清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

医学 心力衰竭 肾功能 射血分数 内科学 肾脏疾病 射血分数保留的心力衰竭 心脏病学 胱抑素C 肌酐 体质指数
作者
Milton Packer,Michael R. Zile,Christopher M. Kramer,Masahiro Murakami,Yang Ou,Barry A. Borlaug
出处
期刊:Journal of the American College of Cardiology [Elsevier BV]
卷期号:85 (18): 1721-1735 被引量:28
标识
DOI:10.1016/j.jacc.2025.03.009
摘要

Obesity leads to both heart failure with a preserved ejection fraction (HFpEF) and to chronic kidney disease (CKD); CKD may both influence the clinical course of obesity-related HFpEF; and incretin-based drugs may influence renal function. This analysis had dual objectives: 1) to evaluate the influence of CKD on the clinical responses to tirzepatide in patients with obesity-related HFpEF; and 2) to investigate the complexity of tirzepatide-related changes in renal function. For both objectives, we focused on discrepancies between creatinine-based and cystatin C-based estimates of the estimated glomerular filtration rate (eGFR). The SUMMIT trial randomly assigned 731 patients with HFpEF and a body mass index ≥30 kg/m2, who were enriched for participants with CKD. Patients received either placebo or tirzepatide for a median of 104 weeks and were followed for cardiovascular death or worsening heart failure events and for changes in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) after 52 weeks. Because of the confounding produced by obesity and changes in muscle mass, eGFR was assessed at randomization and after 12, 24, and 52 weeks by both creatinine-based and cystatin C-based formulae. Patients with CKD (based on creatinine or cystatin C) had greater severity of heart failure, as reflected by: 1) worse functional class, KCCQ-CSS scores, and 6-minute walk distance; 2) higher levels of NT-proBNP and cardiac troponin T; and 3) a 2-fold increase in the risk of worsening heart failure events. CKD did not influence the effect of tirzepatide to reduce the relative risk of major adverse heart failure events and to improve KCCQ-CSS, quality of life, and functional capacity, but the absolute risk reduction in the primary events was numerically greater in patients with CKD. Regarding renal function assessments, baseline eGFR-cystatin C was consistently ≈9 mL/min/1.73 m2 lower than that eGFR-creatinine, with significant individual variance. Furthermore, tirzepatide increased eGFR at 52 weeks, assessed by both creatinine-based and cystatin C-based formulae, but with considerable discordance in individual patients. Tirzepatide produced a decline in eGFR at 12 weeks with eGFR-creatinine (but not eGFR-cystatin C), and it led to an improvement in eGFR at 52 weeks in all patients (when assessed by cystatin C), but only in patients with CKD (when assessed by eGFR-creatinine). The triad of obesity, HFpEF, and CKD identifies patients with considerable functional impairment and an unfavorable prognosis, who nevertheless respond favorably to tirzepatide. Long-term tirzepatide improves renal function (both by cystatin C and creatinine), but the measurement of eGFR in patients with obesity receiving incretin-based drugs is likely to be skewed by the effects of fat and muscle mass (and by changes in body composition) on the synthesis of both cystatin C and creatinine. (A Study of Tirzepatide [LY3298176] in Participants With Heart Failure With Preserved Ejection Fraction [HFpEF] and Obesity: The SUMMIT Trial; NCT04847557).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
15秒前
乐乐的应助被GraceKabiri759采纳,获得30
1分钟前
1分钟前
好运连连发布了新的文献求助10
1分钟前
1分钟前
1分钟前
Agan发布了新的文献求助10
1分钟前
把饭拼好给你完成签到 ,获得积分10
1分钟前
思源的应助被Agan采纳,获得10
1分钟前
好运连连完成签到,获得积分10
2分钟前
2分钟前
2分钟前
五月完成签到,获得积分10
2分钟前
瘦瘦的枫叶完成签到 ,获得积分10
2分钟前
sugar发布了新的文献求助10
2分钟前
传奇3的应助被wuyy采纳,获得10
2分钟前
酷波er的应助被sugar采纳,获得10
2分钟前
Omarkyarm完成签到,获得积分10
2分钟前
2分钟前
wuyy发布了新的文献求助10
2分钟前
圆月弯刀完成签到 ,获得积分10
2分钟前
合适乐巧完成签到 ,获得积分10
3分钟前
null的应助被mashibeo采纳,获得10
3分钟前
wuyy完成签到,获得积分20
3分钟前
赘婿的应助被wuyy采纳,获得10
3分钟前
3分钟前
wuyy发布了新的文献求助10
3分钟前
JUN完成签到,获得积分10
4分钟前
4分钟前
瞿人雄完成签到,获得积分10
4分钟前
没心没肺完成签到,获得积分10
4分钟前
keggin完成签到,获得积分10
4分钟前
4分钟前
alex的应助被科研通管家采纳,获得10
4分钟前
alex的应助被科研通管家采纳,获得10
4分钟前
4分钟前
CHENG驳回了李健的应助
4分钟前
11发布了新的文献求助10
4分钟前
田様的应助被shiqiyuan采纳,获得10
4分钟前
清风完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195184
求助须知:如何正确求助?哪些是违规求助? 9580915
关于积分的说明 21872990
捐赠科研通 7795171
什么是DOI,文献DOI怎么找? 3437967
关于科研通互助平台的介绍 2561276
邀请新用户注册赠送积分活动 2484678